|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, in this study, we aimed for the identification of a GNMT inducer for HCC therapy.
|
27153064 |
2016 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Glycine N-methyltransferase (GNMT) is a folate binding protein commonly diminished in human hepatoma yet its role in tumor development remains to be established.
|
23922098 |
2014 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The findings in this manuscript indicate that DNA hypermethylation plays an important role in the repression of GNMT in HCC and that loss of GNMT in human HCC could promote the establishment of aberrant DNA methylation patterns at specific gene promoters.
|
23475283 |
2013 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In addition, mutations in glycine-N-methyltransferase (GNMT) could be associated with a higher risk of hepatocellular carcinoma and liver disease due to an unbalanced S-adenosylmethionine (SAM)/S-adenosylhomocysteine (SAH) ratio, which leads to aberrant methylation reactions.
|
23474979 |
2013 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
High proportions of GNMT knockout mice developed HCC.
|
23749938 |
2013 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Children with GNMT mutation have elevated liver transaminases, and Gnmt knockout mice develop liver injury, fibrosis, and HCC.
|
23073625 |
2012 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Previously, we reported that glycine N-methyltransferase (GNMT) knockout (Gnmt(-/-)) mice develop chronic hepatitis and HCC.
|
22183894 |
2012 |
|
Liver carcinoma
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Reduced levels of GNMT and phosphorylation of AMPKα at Thr172 and increased levels of Ras, LKB1, and RASGRP3 in HCC samples from patients were associated with shorter survival times.
|
22687285 |
2012 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Integrated gene expression data revealed highest expression of proliferation-related CTGF, c-MYC, and PCNA, and lowest expression of BHMT, DMBT1, DUSP1, GADD45g, and GNMT, in more aggressive rat and human HCC.
|
22434528 |
2012 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
One hundred thirty-three DNA samples (45 cirrhotic nodules, 29 LGDNs, 13 HGDNs, 14 eHCCs, and 32 progressed HCCs (pHCCs)) from HBV-infected resected livers were subjected to MethyLight analysis for nine CpG island loci (APC, RASSF1A, SOCS1, P16, COX2, SPRY2, PTEN, GNMT, and ERK), and COX2, RASSF1A, and SOCS1 protein expression status was analyzed by immunohistochemistry.
|
21145824 |
2011 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, GNMT is a tumor suppressor for HCC and it exerts protective effects in hepatocytes via direct interaction with AFB(1), resulting in reduced AFB(1)-DNA adducts formation and cell death.
|
19146867 |
2009 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Animals were intraperitoneally inoculated with aflatoxin B(1) (AFB(1)) and monitored for 11 months, during which neither male nor female GNMT-TG mice developed HCC.
|
19146867 |
2009 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Animals were intraperitoneally inoculated with aflatoxin B(1) (AFB(1)) and monitored for 11 months, during which neither male nor female GNMT-TG mice developed HCC.
|
19146867 |
2009 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
MGD |
Previously, we described that the expression of GNMT was diminished in human HCC.
|
19035462 |
2009 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Previously, we described that the expression of GNMT was diminished in human HCC.
|
19035462 |
2009 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
MGD |
Glycine N-methyltransferase-/- mice develop chronic hepatitis and glycogen storage disease in the liver.
|
17937387 |
2007 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In a previous study, we showed that GNMT acts as a susceptibility gene for hepatocellular carcinoma.
|
17332283 |
2007 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, in this study, we did not observe the association of polymorphic GNMT alleles as inherited risk factors for HCC.
|
12566309 |
2003 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Therefore, the expression of GNMT was downregulated in human HCC.
|
12566990 |
2003 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
However, in this study, we did not observe the association of polymorphic GNMT alleles as inherited risk factors for HCC.
|
12566309 |
2003 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Previously, we reported that the expression level of GNMT was diminished in human hepatocellular carcinoma.
|
10843803 |
2000 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Characterization of glycine-N-methyltransferase-gene expression in human hepatocellular carcinoma.
|
9495250 |
1998 |
|
Malignant neoplasm of liver
|
0.560 |
AlteredExpression
|
disease |
BEFREE |
Reduced GNMT expression was also found in human HCC tissue and liver cancer cell lines.
|
31086990 |
2019 |
|
Malignant neoplasm of liver
|
0.560 |
AlteredExpression
|
disease |
BEFREE |
High rates of GNMT knockout mice developed HCC, while overexpression of GNMT prevented aflatoxin-induced carcinogenicity and inhibited liver cancer cell proliferation.
|
27153064 |
2016 |
|
Malignant neoplasm of liver
|
0.560 |
Biomarker
|
disease |
CTD_human |
Deficiency of glycine N-methyltransferase results in deterioration of cellular defense to stress in mouse liver.
|
21137059 |
2010 |